Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats

被引:19
作者
El-Batran, SA [1 ]
Abdel-Salam, OME [1 ]
Nofal, SA [1 ]
Baiuomy, AR [1 ]
机构
[1] Natl Res Ctr, Dept Pharmacol, Cairo, Egypt
关键词
insulin; nateglinide; rosiglitazone; metformin; streptozotocin-induced diabetes;
D O I
10.1016/j.phrs.2005.08.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to investigate the effect of I month treatment with nateglinide, rosiglitazone, metformin and their different combinations on streptozotocin (STZ) diabetic rats. Methods: Diabetes was induced by a single intraperitoneal injection of STZ at a dose 55 mg kg(-1). The plasma glucose, total lipid, cholesterol, triglyceride and protein components were measured before and 15 and 30 days after the administration of the antidiabetic agents. Results: After the treatment, a significant reduction was observed in fasting blood glucose levels in all groups. Rosiglitazone or metformin were found to exhibit a hypolipidaemic effect in diabetic rats when administered alone or in combination. In comparison, nateglinide, when used alone, resulted in a significant increase in cholesterol and total lipid levels. This effect was masked when nateglinide was administered concurrently with metformin and hypolipidaemic effect was noticed. Conclusions: Results from this study suggest that compared with nateglinide, rosiglitazone has a more favorable effect on the lipid profile in STZ-induced diabetes in rats. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 45 条
[1]   VETERANS AFFAIRS COOPERATIVE STUDY ON GLYCEMIC CONTROL AND COMPLICATIONS IN TYPE-II DIABETES (VA CSDM) - RESULTS OF THE FEASIBILITY TRIAL [J].
ABRAIRA, C ;
COLWELL, JA ;
NUTTALL, FQ ;
SAWIN, CT ;
NAGEL, NJ ;
COMSTOCK, JP ;
EMANUELE, NV ;
LEVIN, SR ;
HENDERSON, W ;
LEE, HS .
DIABETES CARE, 1995, 18 (08) :1113-1123
[2]  
Armitage P., 1971, STAT METHODS MED RES
[3]   Drug therapy - Metformin [J].
Bailey, CJ ;
Turner, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (09) :574-579
[4]   Untitled - Reply [J].
Boyle, PJ .
CLINICAL THERAPEUTICS, 2002, 24 (08) :1360-1362
[5]   Control of postprandial hyperglycemia - Optimal use of short-acting insulin secretagogues [J].
Carroll, MF ;
Izard, A ;
Riboni, K ;
Burge, MR ;
Schade, DS .
DIABETES CARE, 2002, 25 (12) :2147-2152
[6]   Pharmacologic therapy for type 2 diabetes mellitus [J].
DeFronzo, RA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :281-303
[7]  
Elson D F, 1998, WMJ, V97, P49
[8]   Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial [J].
Fonseca, V ;
Rosenstock, J ;
Patwardhan, R ;
Salzman, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (13) :1695-1702
[9]  
FOSSATI P, 1982, CLIN CHEM, V28, P2077
[10]   Randomised dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166) [J].
Gribble, FM ;
Manley, SE ;
Levy, JC .
DIABETES CARE, 2001, 24 (07) :1221-1225